The Politics of Prostate Cancer Screening

The controversial recent recommendation by the United States Preventive Services Task Force (USPSTF) against prostate-specific antigen (PSA) screening for early-stage prostate cancer has caused much debate. Whereas USPSTF recommendations against routine screening mammography in younger women resulted in fierce public outcry and eventual alteration in the language of the recommendation, the same public and political response has not been seen with PSA screening for prostate cancer. It is of paramount importance to ensure improved efficiency and transparency of the USPSTF recommendation process, and resolution of concerns with the current USPSTF recommendation against PSA screening for all ages.

References

1. Koss L.G.: The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989; 261: pp. 737
2. Schroder F.H., Hugosson J., Roobol M.J., et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: pp. 1320
3. National comprehensive cancer network guidelines and derivative information products: user guide. 2013. Available at: http://www.nccn.org/clinical.asp. Accessed February 12, 2014.
4. Heidenreich A., Bastian P.J., Bellmunt J., et al: EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: pp. 124-137
5. USPSTF: About the United States Preventive Services Task Force. Rockville (MD); 2013. Available at: http://www.uspreventiveservicestaskforce.org/about.htm. Accessed February 12, 2014.
6. Brawley O., Byers T., Chen A., et al: New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA 2011; 306: pp. 2495
7. Moyer V.A.: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: pp. 120
8. Andriole G.L., Crawford E.D., Grubb R.L., et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: pp. 1310
9. Etzioni R., Gulati R., Cooperberg M.R., et al: Limitations of basing screening policies on screening trials: the US Preventive Services Task Force and Prostate Cancer Screening. Med Care 2013; 51: pp. 295
10. Yao S.L., and Lu-Yao G.: Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst 1999; 91: pp. 1950
11. Hugosson J., Carlsson S., Aus G., et al: Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: pp. 725
12. Penson D.F., and Chan J.M.: Prostate cancer. J Urol 2007; 177: pp. 2020
13. Labrie F., Candas B., Dupont A., et al: Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: pp. 83
14. Labrie F., Candas B., Cusan L., et al: Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: pp. 311
15. Sandblom G., Varenhorst E., Lofman O., et al: Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004; 46: pp. 717
16. U.S. Preventive Services Task Force : Screening for prostate cancer: recommendation and rationale. Ann Intern Med 2002; 137: pp. 915
17. Harris R., and Lohr K.N.: Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: pp. 917
18. Jacobsen S.J., Bergstralh E.J., Katusic S.K., et al: Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology 1998; 52: pp. 173
19. Richert-Boe K.E., Humphrey L.L., Glass A.G., et al: Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen 1998; 5: pp. 99
20. U.S. Preventive Services Task Force : Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: pp. 185
21. Lin K., Lipsitz R., Miller T., et al: Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: pp. 192
22. Bill-Axelson A., Holmberg L., Ruutu M., et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: pp. 1977
23. Chou R., Croswell J.M., Dana T., et al: Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155: pp. 762
24. US Preventive Services Task Force : Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151: pp. 716
25. Mandelblatt J.S., Cronin K.A., Bailey S., et al: Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009; 151: pp. 738
26. Hendrick R.E., and Helvie M.A.: Mammography screening: a new estimate of number needed to screen to prevent one breast cancer death. AJR Am J Roentgenol 2012; 198: pp. 723
27. Etzioni R., Tsodikov A., Mariotto A., et al: Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008; 19: pp. 175
28. Qaseem A., Barry M.J., Denberg T.D., et al: Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013; 158: pp. 761
29. Heidenreich A., Abrahamsson P.A., Artibani W., et al: Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol 2013; 64: pp. 347-354
30. National Comprehensive Cancer Network: prostate cancer early detection. 2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed February 12, 2014.
31. Carter H.B., Albertsen P.C., Barry M.J., et al: Early detection of prostate cancer: AUA guideline. J Urol 2013; 190: pp. 419